Khiron Life Sciences operates like a pharmaceutical company, commercializing medical cannabis products, operating trauma treatment facilities and developing pharma-grade beauty products throughout Latin America. Khiron’s model focuses on the patient, fulfilling their needs and understanding their expectations. Khiron prides itself on the development of a safe, consistent and high-quality product which enhances wellbeing for body and mind.




Highlights of their most recent developments are:

  • On June 19, 2019, Khiron completed the acquisition of NettaGrowth International and its wholly-owned subsidiary Dormul S.A., providing the Company with an additional 120 tonnes of licensed production capacity and entry into the Uruguay market.
  • On August 6, 2019, Khiron and Dixie Brands received conditional approval from the TSX.V for the distribution and sale of Kuida cosmeceutical products in the U.S. Dixie aims to distribute Khiron’s portfolio of Kuida cosmeceutical products throughout the U.S. in early 2020, while also targeting a LatAm commercialization of Dixie CBD-infused products for the first half of 2020.
  • Khiron’s subsidiary in Peru has received authorization to register as a pharmacy by the Ministry of Health of Peru, a crucial step to obtaining import and commercialization licenses for medical cannabis products, once all final regulatory approvals in Peru are finalized.
  • Khiron’s distribution channels for Kuida were expanded substantially and sales of the products are on the rise: As of August 2019, the Company has signed distribution agreements for at least 190 stores across various retailers in Colombia.
  • In July, the Company was the sole cannabis company to participate in the XLIV International Course of Internal Medicine conference in Monterrey, Mexico. The conference hosted over 2,000 physicians and medical specialists to discuss medical cannabis developments and knowledge.

Last updated: September, 2019